Over the 5 years following a single steroid injection, prescriptions for opioid-nonopioid combination products (e.g., ...
Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) TD Cowen 45th Annual Health Care Conference Transcript March 3, 2025 3:10 PM ET David Altshuler - Executive Vice President, Global Research and CSO ...
The company has chosen to move ahead to Phase III trials with its 10mg dose after it saw a 1.74-point reduction in pain score ...
Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...
Lexicon Pharmaceuticals is yet again defending a mixed set of data on its non-opioid pain prospect. | Lexicon Pharmaceuticals ...
Lexicon's non-opioid drug pilavapadin fails Phase 2b pain trial at 20mg dose, but shows promise at 10mg. Company plans Phase ...
Mexico has handled the cartels so poorly that it broke international law. It is obligated to prevent the harm cartels are ...